|
April 30, 2024
|
Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
April 30, 2024
|
Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer
|
|
April 29, 2024
|
Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024
|
|
April 17, 2024
|
Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
|
|
March 6, 2024
|
Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference
|
|
February 7, 2024
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET
|
|
February 6, 2024
|
Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
|
|
January 31, 2024
|
Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023
|
|
January 4, 2024
|
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
January 3, 2024
|
Enanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|